Variants in the APOL1 gene are thought to be important contributors to a disparity in the incidence of ESKD among Black people, which is approximately three-fold higher than among White people. No specific treatment or management protocol for APOL1-associated nephropathy currently exists. Using a Delphi consensus process supported by a systematic literature review, a multidisciplinary group agreed on practical measures for care of patients who may have APOL1-associated nephropathy. The recommendations address three areas: (1) counseling, genotyping, and diagnosis; (2) disease awareness and education; and (3) a future vision for the management of patients with APOL1 high-risk genotypes. These recommendations may help clinicians improve awareness and diagnosis of APOL1-associated nephropathy and by doing so, may provide opportunities to reduce health disparities related to kidney disease.